Literature DB >> 34942201

First nosocomial cluster of COVID-19 due to the Delta variant in a major acute care hospital in Singapore: investigations and outbreak response.

W-Y Lim1, G S E Tan2, H L Htun3, H P Phua3, W M Kyaw3, H Guo3, L Cui4, T M Mak4, B F Poh5, J C C Wong6, Y X Setoh6, B S P Ang7, A L P Chow8.   

Abstract

OBJECTIVES: The first large nosocomial cluster of coronavirus disease 2019 (COVID-19) in Singapore in April 2021 led to partial closure of a major acute care hospital. This study examined factors associated with infection among patients, staff and visitors; investigated the possible role of aerosol-based transmission; evaluated the effectiveness of BNT162.b2 and mRNA1273 vaccines; and described the successful containment of the cluster.
METHODS: Close contacts of patients with COVID-19 and the affected ward were identified and underwent surveillance for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Patient, staff and visitor cohorts were constructed and factors associated with infection were evaluated. Phylogenetic analysis of patient samples was performed. Ward air exhaust filters were tested for SARS-CoV-2.
RESULTS: In total, there were 47 cases, comprising 29 patients, nine staff, six visitors and three household contacts. All infections were of the Delta variant. Ventilation studies showed turbulent air flow and swabs from air exhaust filters were positive for SARS-CoV-2. Vaccine breakthrough infections were seen in both patients and staff. Among patients, vaccination was associated with a 79% lower odds of infection with COVID-19 (adjusted odds ratio 0.21, 95% confidence interval 0.05-0.95).
CONCLUSIONS: This cluster occurred despite enhancement of infection control measures that the hospital had undertaken at the onset of the COVID-19 pandemic. It was brought under control rapidly through case isolation, extensive contact tracing and quarantine measures, and led to enhanced use of hospital personal protective equipment, introduction of routine rostered testing of inpatients and staff, and changes in hospital infrastructure to improve ventilation within general wards.
Copyright © 2021 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  COVID-19; COVID-19 vaccines; Infection control; Outbreak; Phylogeny

Mesh:

Year:  2021        PMID: 34942201      PMCID: PMC8687717          DOI: 10.1016/j.jhin.2021.12.011

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   8.944


Introduction

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has spread rapidly around the world with over 250 million cases reported by 1st November 2021. New variants of concern have also been identified, including the Delta variant [1], which have rapidly replaced the original strain and led to surges in infections globally. Singapore has registered more than 201,000 cases of COVID-19 and 412 deaths from COVID-19-related complications. Prior to August 2021, Singapore maintained a containment strategy that aimed to detect, isolate and contact trace every case of confirmed COVID-19. Tan Tock Seng Hospital is a 1600-bed multi-disciplinary acute care hospital in Singapore. Prior to this cluster, visitors to the hospitals as well as outpatients were required to use a face mask (surgical or fabric mask) by law. Admitted patients were encouraged to use face masks if their condition permitted. Entry swabs were performed where there was suggestive clinical [e.g. symptoms of acute respiratory infection (ARI)] or contact history, and visitors with ARI symptoms were restricted from entering the hospital. A multi-pronged approach to protect staff against COVID-19 – which includes routine use of surgical masks for patient interactions; N95 respirators and eye protection, gowns and gloves when performing high-risk aerosol-generating procedures (AGPs) or interacting with known or suspected cases of COVID-19; daily temperature monitoring; and active surveillance for ARI – has also been implemented since January 2020 [2]. With these measures, nosocomial transmission of SARS-CoV-2 did not occur in the hospital until April 2021 [3,4], when the first large nosocomial cluster of COVID-19 in Singapore occurred with the Delta variant. This study examined factors associated with infection among patients, staff and visitors; investigated the possible role of aerosol-based transmission; evaluated the effectiveness of BNT162.b2 and mRNA1273 vaccines; and described the successful containment of the cluster.

Methods

The outbreak occurred in General Ward I, a 43-bed facility comprising six six-bed cubicles separated by floor-to-ceiling side-walls, a two-bed isolation room, a single-bedroom used for end-of-life patients, one enclave bed, three temporary corridor beds that are used during periods of high hospital occupancy, and common toilets and showers. The ward is equipped with air conditioners that are turned on when indoor ambient temperatures exceed 27 °C. The index case, a nurse (Patient A) on Ward I, presented with fever on 27th April 2021 and a positive nasopharyngeal swab for SARS-CoV-2 later that night. On 28th April 2021, a symptomatic physician (Patient B) who had seen patients on Ward I tested positive for SARS-CoV-2, as did a patient (Patient C) who had been lodged on Ward I since 20th April 2021. In response, the ward was closed on 28th April 2021. Epidemiological investigations, contact tracing and quarantine of close contacts were performed. In addition, all hospital staff were swabbed and screened weekly, and a thorough review of all existing infection control measures was taken. Patients who were still on Ward I at the time of closure (28th April 2021) were transferred to isolation rooms, placed on active clinical surveillance, and underwent nasal/throat swabs for SARS-CoV-2 polymerase chain reaction (PCR) tests (every 1–3 days). Discharged patients, visitors to Ward I, and household contacts of COVID-19 cases were issued 14-day quarantine orders by the Ministry of Health Singapore, swabbed on entry to and exit from quarantine, and thereafter required to further isolate at home for another 7 days. Staff were quarantined, and swabbed at days 7, 14 and 21 from the last date of contact with a confirmed case or with Ward I. All PCR tests were performed in accredited laboratories using a nationally approved PCR test protocol. Close contacts (individuals exposed for ≥15 min within 2 m of a confirmed case of COVID-19), and patients, staff and visitors who spent ≥15 min cumulatively in Ward I from 20th April 2021 (the date that Patient C was admitted to Ward I) to 28th April 2021 (date of ward closure) were identified. This was accomplished through reviews of electronic medical records, staff duty rosters, patient and visitor registration records, closed-circuit television footage, data from a real-time location system [5] that was used in the emergency department (ED), and self-reporting via an internet-based survey platform. Three cohorts were constructed: (i) patients admitted to Ward I; (ii) visitors to Ward I; and (iii) staff based on Ward I (e.g. nurses, healthcare assistants, housekeepers) and non-ward-based staff (allied health professionals) rostered to Ward I. The following variables were collected: (i) patients: demographics, co-morbidities, mobility status, receipt of potential aerosol-generating procedures (AGPs) (open suctioning of endotracheal or tracheostomy tubes, nebulizer treatment, sputum induction and high-flow oxygen supplementation), SARS-CoV-2 vaccination status, date of COVID-19 symptom onset, dates and times of admission and discharge from Ward I, and bed location within the ward; (ii) visitors: dates and times of visits to Ward I, and the patient visited; and (iii) healthcare workers: demographics, SARS-CoV-2 vaccination status, duration of exposure in Ward I, and patient(s) on Ward I for whom care was provided. Standard descriptive statistics of distribution and measures of central tendency were performed. Multiple logistic regression was used to assess factors associated with COVID-19. All reported P-values were two-tailed, with an α level of 0.05. Statistical analyses were conducted using Stata Version 13.1 (StataCorp LLC, College Station, TX, USA). Whole-genome sequencing of SARS-Co-V-2 samples was performed as described [6]. Insertion/deletion mutations were screened using Freebayes [7], and verified in consensus sequences after examining raw reads. Only sequences that were 98% complete and supported by an average coverage of 100x were shared via GISAID [8] and included. All sequences were aligned using MAFFT v7.427 [9]. The maximum-likelihood tree was inferred using IQ-TREE v2.0.3 with best-fit model, ultrafast bootstrap approximation [[10], [11], [12], [13]] and hCoV-19/Wuhan/WIV04/2019 (accession EPI_ISL_402124) as a reference root. Additionally, the closest available Delta sequences were downloaded from GISAID and added as references. Air exhaust filters from the air-conditioning system in Ward I were extracted, and the entire surface of each filter (each measuring 970 x 370 x20 mm, made of synthetic fibre) was swabbed with two to three swabs (Eswab; COPAN, Murrieta, CA, USA) and collected in viral transport medium [14]. Material was dislodged by vortexing, and clarified by centrifugation. The supernatant was subjected to RNA purification (MagMAX/Kingfisher; ThermoFisher, Waltham, MA, USA), followed by an N1-specific TaqMan assay performed in triplicate to detect SARS-CoV-2 RNA [15]. Data collection and analyses were performed as part of the hospital's outbreak response, and approved for publication by the Domain Specific Review Board of National Healthcare Group (Ref. No. 2021/00511).

Results

Case finding identified 47 cases in the cluster, comprising 29 patients (28 from Ward I, one from Ward II), nine staff, six visitors to Ward I and three household contacts. While the majority of these 47 cases had mild infections, four deaths (three of which were attributed to COVID-19) occurred in patients who had multiple co-morbidities and had not received SARS-CoV-2 vaccination. Contact tracing identified a total of 220 patients (admitted to Ward I or II between 20th and 28th April 2021, or from other wards who were close contacts of infected medical staff), 416 staff who were close contacts of cases of COVID-19, 634 other staff who had spent at least 15 min on Ward I or Ward II, and 741 visitors to either ward. In addition, 11,004 asymptomatic hospital staff were screened weekly for SARS-CoV-2 without any covert infection detected [16]. The epidemic curve of 36 cases who were symptomatic (Figure 1 ) is consistent with a point source outbreak, although epidemiological investigations suggest that there were at least three cases of secondary transmission. Patient C was most likely the primary case.
Figure 1

Epidemic curve observed in the Ward I cluster.

Epidemic curve observed in the Ward I cluster. Patient C presented at the ED on 18th April 2021 with a 3-day history of fever, upper respiratory symptoms and headache. A nasopharyngeal swab for SARS-CoV-2 was negative and chest X-ray was normal. The clinical impression was a sinus infection with scalp cellulitis, and the patient was admitted to another ward before being transferred to Ward I on 20th April 2021. He was first admitted to a bed in Cubicle 6 on 20th April 2021, and transferred to Cubicle 1 on 22nd April 2021. The patient's fever resolved in response to antibiotics, but recurred on 22nd April 2021. A computed tomography scan of the abdomen and pelvis to investigate the cause of persistent fever showed ground glass opacities in the lower lung fields. The patient was then isolated, and a second PCR swab, performed on 28th April 2021, was positive for COVID-19. Patient D was admitted to Ward II on 19th April 2021, and remained there until a PCR swab tested positive on 29th April 2021. The patient (unvaccinated) had no contact with any patients with COVID-19 or staff from Ward I. No other patients on Ward II tested positive. Wards I and II are separate wards with independent ventilation systems, but are connected by an internal corridor (Figure 3 ), which leads to a shared physiotherapy area. This area was used by several COVID-19-positive patients and staff from Ward I between 20th and 28th April 2021.
Figure 3

Bed location of all patient cases of coronavirus disease 2019 in the Ward I cluster, and air exhaust filter swab results. SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; PCR, polymerase chain reaction.

Phylogenetic relationship of severe acute respiratory syndrome coronavirus-2 sequences, as generated by IQTree with γ-distributed rate differences and 1000 bootstrap validation. All sequences were identified by GISAID accession numbers, with global and Singapore references in magenta and black, respectively. Cases related to Ward I are in blue (Node 18). The scale bar indicates genetic distance between sequences, and bootstrap values are indicated at node branches. Samples from Patient A (index case), Patient B (symptomatic physician), Patient C (primary case) and Patient D (patient from Ward II) are shown. Bed location of all patient cases of coronavirus disease 2019 in the Ward I cluster, and air exhaust filter swab results. SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; PCR, polymerase chain reaction. All samples from 39 cases in the Ward I COVID-19 cluster were of the Delta variant, clustering on the same branch with 100% bootstrap validation (Figure 2). The remaining cases could not be sequenced adequately due to low viral load. This supported the epidemiological findings of a single introduction event of SARS-CoV-2 into Ward I. The virus from the patient in neighbouring Ward II and non-ward-based staff also clustered on this branch. No patient, staff or visitor from the first ward that Patient C had been admitted to tested positive for SARS-CoV-2.
Figure 2

Phylogenetic relationship of severe acute respiratory syndrome coronavirus-2 sequences, as generated by IQTree with γ-distributed rate differences and 1000 bootstrap validation. All sequences were identified by GISAID accession numbers, with global and Singapore references in magenta and black, respectively. Cases related to Ward I are in blue (Node 18). The scale bar indicates genetic distance between sequences, and bootstrap values are indicated at node branches. Samples from Patient A (index case), Patient B (symptomatic physician), Patient C (primary case) and Patient D (patient from Ward II) are shown.

The cubicle with the largest number of COVID-19 infections in this cluster (Cubicle 2) was not either of the cubicles to which the primary case was admitted. No patients in Cubicle 5 acquired COVID-19, although this cubicle was fully occupied throughout the risk period (Figure 3). Air filters from various locations in the ward were extracted approximately 9 days after the ward was closed, swabbed and tested for SARS-CoV-2. Air filters from Cubicles 1 and 2 and the nursing station were positive for SARS-CoV-2, with Cubicle 2 having the greatest proportion of swabs that were positive (Figure 3). All swabs from air filters in Cubicles 1 (location of Patient D) and 2 of Ward II were negative. Of the 92 patients in Ward I between 20th and 28th April 2021, the attack rate was 30.4% (28 infected). The mean length of stay on the ward was significantly longer for patients with COVID-19 than non-cases (5.6 ± 2.7 days vs 3.0 ± 2.7 days; P<0.001). The adjusted odds of infection increased with duration of exposure on the ward [adjusted odds ratio (OR) 1.38, 95% confidence interval (CI) 1.14–1.68]. The odds of infection increased with ward stay in the later part of the period 20th–28th April, and was estimated to be 5.68 times higher for ward stay on 27th April (95% CI 1.30–24.87) compared with not staying on the ward that day (Figure 4 ). Patients in Cubicle 2 (adjusted OR 23.98, 95% CI 3.44–167.01) and in corridor beds (adjusted OR 9.56, 95% CI 1.49–61.15) had higher odds of acquiring COVID-19.
Figure 4

Adjusted odds ratio for stay in Ward I on specific days during the period from 20th to 28th April 2021. Note: Each model was adjusted for the following variables: age, gender, co-morbidities (diabetes mellitus, malignancies, leukaemia, lymphoma, connective tissue disease, chronic lung disease, congestive cardiac failure), whether patient had received at least one dose of coronavirus disease 2019 vaccine, and duration on the ward.

Adjusted odds ratio for stay in Ward I on specific days during the period from 20th to 28th April 2021. Note: Each model was adjusted for the following variables: age, gender, co-morbidities (diabetes mellitus, malignancies, leukaemia, lymphoma, connective tissue disease, chronic lung disease, congestive cardiac failure), whether patient had received at least one dose of coronavirus disease 2019 vaccine, and duration on the ward. More than one-third (34.4%, 22/64) of non-cases had at least one dose of SARS-CoV-2 vaccine, approximately twice the proportion (17.9%, 5/28) in patient cases (P=0.139) (See online supplementary material Table S1). Having had at least one dose of the vaccine was associated with a 79% lower odds of infection (adjusted OR 0.21, 95% CI 0.05–0.95) (Table I ).
Table I

Odds ratio associated with acquiring coronavirus disease 2019 (COVID-19) among patients on Ward I between 20th and 28th April 2021

VariableUnivariable logistic regression
Multiple logistic regression
OR95% CIP-valueAdjusted ORb95% CIP-value
Age (years)
 <70Reference groupReference group
 70–791.900.57–6.320.2922.000.48–8.410.345
 80–891.250.38–4.160.7161.520.36–6.360.569
 ≥905.361.17–24.430.0306.260.88–44.50.067
Gender
 FemaleReference groupReference group
 Male0.750.31–1.830.5290.580.19–1.720.326
With selected co-morbiditiesa
 NoReference groupReference group
 Yes2.410.97–5.990.0583.091.00–9.540.050
Had at least one dose of COVID-19 vaccine
 NoReference groupReference group
 Yes0.420.14–1.240.1160.210.05–0.950.043
Days on Ward I between 20th and 28th April 20211.361.15–1.61<0.00011.381.14–1.680.001

OR, odds ratio; CI, confidence interval.

Co-morbidities included were diabetes mellitus, malignancies, leukaemia, lymphoma, connective tissue disease, chronic lung disease and congestive cardiac failure.

Adjusted for all variables in the table.

Odds ratio associated with acquiring coronavirus disease 2019 (COVID-19) among patients on Ward I between 20th and 28th April 2021 OR, odds ratio; CI, confidence interval. Co-morbidities included were diabetes mellitus, malignancies, leukaemia, lymphoma, connective tissue disease, chronic lung disease and congestive cardiac failure. Adjusted for all variables in the table. Ten potential AGPs were performed on five patients on the ward during the risk period, of which six (all nebulizer treatments) were carried out on two patients with COVID-19, while four (two nebulizers, two high-flow oxygen administrations) were performed on three non-COVID-19 cases. All such procedures performed on the two patients with COVID-19 took place at least 48 h prior to symptom onset and were not performed by the two affected nurses. The nine staff who became infected included two physicians, two Ward I nurses, one physiotherapist, one pharmacist, one housekeeper, one porter and one ED nurse (See online supplementary material Table S2). Similar proportions of staff cases and non-cases had at least one dose of the SARS-CoV-2 vaccine (87.5% vs 87.1%, P=1.000). All ward-based staff cases (N=5, i.e. excluding the two physicians, porter and ED nurse) were close contacts of a case, compared with less than half of the ward-based staff non-cases (P=0.028); and these cases spent significantly longer periods of time on the ward (median 37.0 vs 5.0 h; P=0.024) but duration on the ward was no longer significant after adjustment. The attack rate among ward-based staff was 3.9% (five of 129 staff) (See online supplementary material Table S3). Six visitors (1.9%) were infected out of 309 visitors to Ward I. The median cumulative duration of visits to Ward I among visitor cases was significantly longer compared with non-cases (335.9 vs 63.0 min; P=0.036), and the median number of visits was also significantly higher (3 vs 1; P=0.025). Compared with non-cases, a higher proportion of visitor cases were close contacts of a patient case [66.7% (4/6) vs 12.2% (37/303); P=0.003]. In adjusted analyses, being a close contact was associated with infection (adjusted OR 12.61, 95% CI 2.15–74.01). Visitors to Cubicle 2 were not at higher odds of acquiring COVID-19 (See online supplementary material Table S4).

Discussion

Containment of this cluster of COVID-19 Delta variant in a general ward of an acute care hospital involved the identification and quarantine of a large number of individuals (2011 in total). The risk of infection was highest for those who were close contacts of cases, and who spent a longer duration on the ward. Bed location was important but, unusually, the highest risk did not occur among those who were in the same cubicle as the primary case. Vaccination reduced the risk of infection. Contact and short-range droplet/aerosol spread from the index case were the most likely modes of transmission: close contact with a COVID-19 case was associated with increased risk of COVID-19 in visitors, and all Ward-I-based staff cases were close contacts of a patient with COVID-19. However, there were five cases where close contact with a patient with COVID-19 could not be identified: Patient D from Ward II, three staff (including one who spent only 15 min on Ward I), and one visitor to the ward. This suggests the involvement of fomite and/or long-range aerosol transmission in this cluster, the latter of which is corroborated by filter swab studies and is consistent with other reports of aerosol transmission [[17], [18], [19]]. The high similarity of viruses among the cases supports the hypothesis that this cluster is due to a single introduction event. No sequence from other local community cases has been grouped together with this cluster (data not shown), suggesting that outbreak response and control measures were sufficient to prevent wider community transmission. It is notable that this first COVID-19 nosocomial cluster occurred with the Delta variant, which has been reported to be up to 97% more transmissible than the original strain [20,21]. Having had at least one dose of the vaccine reduced the risk of COVID-19 almost five-fold among Ward I patients, suggesting that mRNA-based vaccines protect against the Delta variant of SARS-CoV-2, and this is consistent with a recent report from Public Health England [22]. Klompas et al. [23] recently described a COVID-19 outbreak in Brigham and Women's Hospital, Boston, USA with similar findings and reported comparable strategies in containing the outbreak. The authors noted several important lessons in their outbreak, including the limitations of admission testing, and the potential value of serial testing to identify infections incubating on admission. The present cluster shared many similarities with theirs, and further emphasized the importance of maintaining a high index of suspicion in patients with suggestive symptoms despite an initial negative test. The PPE regime used previously at the study hospital had proven effective against the original SARS-CoV-2 strain, but the more-infectious Delta variant appears to require enhanced measures. As a consequence of this outbreak, the hospital stepped up PPE to routine N95 respirators and eye protection for all staff on inpatient wards, introduced entry swabs for all inpatients, and rostered routine SARS-CoV-2 testing for all staff and inpatients. Staff were required to eat alone at designated eating areas, seated at least 2 m apart wherever practicable or with the use of tables with impermeable plastic dividers. With the new understanding and reports about the role of aerosol transmission, and some preliminary airflow studies performed internally that suggested impaired ventilation as a contributory cause, high-speed extraction fans were also installed in all general wards to improve air circulation. Although many countries in Europe and North America have gradually relaxed community measures as vaccination rates increased, infection rates are starting to rise again, partly due to circulation of the more-infectious Delta variant. With the onset of the winter season, there is a risk of a rapid increase in infection rates in the coming months. The need to reduce nosocomial transmission remains important, even as many countries shift to a ‘live with COVID-19’ or mitigation strategy, as hospital patients are more likely to be vulnerable to severe disease and are also more likely to be unvaccinated due to medical reasons. Investigation of the study cluster highlights several key points: transmission can occur through a mixture of routes, and long-range airborne transmission could play an important role, as reported by other authors [24]; transmission can occur even with very short exposure times; and breakthrough infections and subsequent transmission remain a risk in highly vaccinated environments such as hospital settings, and enhanced measures may be required to prevent nosocomial clusters. Key limitations of this study are that common and frequent interactions between staff and patients made network analysis unfeasible. In addition, the small number of infected staff of each staff type did not permit delineation of high-risk activities. In conclusion, this cluster occurred despite the enhancement of infection control measures at the study hospital at the onset of the COVID-19 pandemic. Fortunately, this cluster was brought under control rapidly through case isolation, extensive contact tracing and quarantine measures. Coinciding with the introduction of the Delta variant into Singapore, and occurring after 1.5 years with no nosocomial transmission, this cluster and the subsequent investigations have led to changes in the use of PPE by staff, implementation of routine rostered COVID-19 testing of inpatients and staff, and enhancements to the hospital infrastructure to improve ventilation within general wards.
  20 in total

1.  Jalview Version 2--a multiple sequence alignment editor and analysis workbench.

Authors:  Andrew M Waterhouse; James B Procter; David M A Martin; Michèle Clamp; Geoffrey J Barton
Journal:  Bioinformatics       Date:  2009-01-16       Impact factor: 6.937

2.  GISAID: Global initiative on sharing all influenza data - from vision to reality.

Authors:  Yuelong Shu; John McCauley
Journal:  Euro Surveill       Date:  2017-03-30

3.  Responding to the COVID-19 Outbreak in Singapore: Staff Protection and Staff Temperature and Sickness Surveillance Systems.

Authors:  Htet Lin Htun; Dwee Wee Lim; Win Mar Kyaw; Wan-Ning Janis Loh; Lay Tin Lee; Brenda Ang; Angela Chow
Journal:  Clin Infect Dis       Date:  2020-11-05       Impact factor: 9.079

Review 4.  Dismantling myths on the airborne transmission of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).

Authors:  J W Tang; W P Bahnfleth; P M Bluyssen; G Buonanno; J L Jimenez; J Kurnitski; Y Li; S Miller; C Sekhar; L Morawska; L C Marr; A K Melikov; W W Nazaroff; P V Nielsen; R Tellier; P Wargocki; S J Dancer
Journal:  J Hosp Infect       Date:  2021-01-13       Impact factor: 3.926

5.  A SARS-CoV-2 Cluster in an Acute Care Hospital.

Authors:  Michael Klompas; Meghan A Baker; Chanu Rhee; Robert Tucker; Karen Fiumara; Diane Griesbach; Carin Bennett-Rizzo; Hojjat Salmasian; Rui Wang; Noah Wheeler; Glen R Gallagher; Andrew S Lang; Timelia Fink; Stephanie Baez; Sandra Smole; Larry Madoff; Eric Goralnick; Andrew Resnick; Madelyn Pearson; Kathryn Britton; Julia Sinclair; Charles A Morris
Journal:  Ann Intern Med       Date:  2021-02-09       Impact factor: 25.391

6.  SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination.

Authors:  Markus Hoffmann; Heike Hofmann-Winkler; Nadine Krüger; Amy Kempf; Inga Nehlmeier; Luise Graichen; Prerna Arora; Anzhalika Sidarovich; Anna-Sophie Moldenhauer; Martin S Winkler; Sebastian Schulz; Hans-Martin Jäck; Metodi V Stankov; Georg M N Behrens; Stefan Pöhlmann
Journal:  Cell Rep       Date:  2021-06-29       Impact factor: 9.423

7.  SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India.

Authors:  Sarah Cherian; Varsha Potdar; Santosh Jadhav; Pragya Yadav; Nivedita Gupta; Mousumi Das; Partha Rakshit; Sujeet Singh; Priya Abraham; Samiran Panda; Nic Team
Journal:  Microorganisms       Date:  2021-07-20

8.  Asymptomatic health-care worker screening during the COVID-19 pandemic.

Authors:  Angela Chow; Htet Lin Htun; Win Mar Kyaw; Lay Tin Lee; Brenda Ang
Journal:  Lancet       Date:  2020-10-31       Impact factor: 79.321

9.  Human neutralising antibodies elicited by SARS-CoV-2 non-D614G variants offer cross-protection against the SARS-CoV-2 D614G variant.

Authors:  Cheryl Yi-Pin Lee; Siti Naqiah Amrun; Rhonda Sin-Ling Chee; Yun Shan Goh; Tze-Minn Mak; Sophie Octavia; Nicholas Kim-Wah Yeo; Zi Wei Chang; Matthew Zirui Tay; Anthony Torres-Ruesta; Guillaume Carissimo; Chek Meng Poh; Siew-Wai Fong; Wang Bei; Sandy Lee; Barnaby Edward Young; Seow-Yen Tan; Yee-Sin Leo; David C Lye; Raymond Tp Lin; Sebastien Maurer-Stroh; Bernett Lee; Cheng-I Wang; Laurent Renia; Lisa Fp Ng
Journal:  Clin Transl Immunology       Date:  2021-02-22

10.  Use of surveillance technology to enhance exposure management for healthcare workers during the COVID-19 pandemic.

Authors:  H J Ho; W Y Lim; B Ang; A Chow
Journal:  J Hosp Infect       Date:  2020-09-24       Impact factor: 3.926

View more
  7 in total

1.  Genomic epidemiology of Delta SARS-CoV-2 during transition from elimination to suppression in Aotearoa New Zealand.

Authors:  Lauren Jelley; Jordan Douglas; Xiaoyun Ren; David Winter; Andrea McNeill; Sue Huang; Nigel French; David Welch; James Hadfield; Joep de Ligt; Jemma L Geoghegan
Journal:  Nat Commun       Date:  2022-07-12       Impact factor: 17.694

2.  Staff and patient surveillance in hospitals: Good sentinels for the emergence of new SARS-CoV-2 variants.

Authors:  Rhea Khanna; Htet Lin Htun; Anthony Lianjie Li; Win Mar Kyaw; Hou Ang; Brenda Ang; Angela Chow
Journal:  J Infect       Date:  2022-07-08       Impact factor: 38.637

3.  Nosocomial Outbreak by Delta Variant From a Fully Vaccinated Patient.

Authors:  Jiwon Jung; Jungmin Lee; Heedo Park; Young-Ju Lim; Eun Ok Kim; Man-Seong Park; Sung-Han Kim
Journal:  J Korean Med Sci       Date:  2022-05-02       Impact factor: 5.354

4.  Impact of Rigorous Clinical and Laboratory Screening for COVID-19 in a Teaching Hospital in Inner Brazil.

Authors:  Stephanie Valentini Ferreira Proença; Carlos Magno Castelo Branco Fortaleza; Jonas Atique Sawazaki; Ricardo de Souza Cavalcante; Bruno Cardoso de Macedo; Sandra Mara Queiroz; Sebastião Pires Ferreira Filho; Gabriel Berg de Almeida
Journal:  Infect Control Hosp Epidemiol       Date:  2022-03-07       Impact factor: 3.254

Review 5.  Fending off Delta - Hospital measures to reduce nosocomial transmission of COVID-19.

Authors:  Rachel Hui Fen Lim; Htet Lin Htun; Anthony Lianjie Li; Huiling Guo; Win Mar Kyaw; Aung Aung Hein; Brenda Ang; Angela Chow
Journal:  Int J Infect Dis       Date:  2022-02-04       Impact factor: 12.074

6.  Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.

Authors:  Oon Tek Ng; Kalisvar Marimuthu; Nigel Lim; Ze Qin Lim; Natascha May Thevasagayam; Vanessa Koh; Calvin J Chiew; Stefan Ma; Mingshi Koh; Pin Yan Low; Say Beng Tan; Joses Ho; Sebastian Maurer-Stroh; Vernon J M Lee; Yee-Sin Leo; Kelvin Bryan Tan; Alex R Cook; Chorh Chuan Tan
Journal:  JAMA Netw Open       Date:  2022-08-01

7.  A Two-Ward Acute Care Hospital Outbreak of SARS-CoV-2 Delta Variant Including a Point-Source Outbreak Associated with the Use of a Mobile Vital Signs Cart and Sub-Optimal Doffing of Personal Protective Equipment.

Authors:  Heidi M O'Grady; Robyn Harrison; Kate Snedeker; Lisa Trufen; Ping Yue; Linda Ward; Abraham Fifen; Peter Jamieson; Amanda Weiss; Jennifer Coulthard; Tarah Lynch; Matthew A Croxen; Vincent Li; Kanti Pabbaraju; Anita Wong; Hong Yuan Zhou; Tanis C Dingle; Kim Hellmer; Byron M Berenger; Kevin Fonseca; Yi-Chan Lin; David Evans; John M Conly
Journal:  J Hosp Infect       Date:  2022-10-01       Impact factor: 8.944

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.